The Faculty of Medicine - Immunology and Cancer Research: Lotem Michal

1.

Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, et al. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology [Internet]. 2023;41(24):3998–4003. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168254736&doi=10.1200%252fJCO.22.01599&partnerID=40&md5=59d6deff4d493e4832f7ddf579f84543

2.

Talmon A, Elias S, Rubin L, Ribak Y, Ben Dori E, Shamriz O, et al. Dupilumab for cancer-associated refractory pruritus. Journal of Allergy and Clinical Immunology: Global [Internet]. 2023;2(3). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164439773&doi=10.1016%252fj.jacig.2023.100128&partnerID=40&md5=7b375be23fddb46d326782d1fa429f2a

3.

Friedman N, Weinstein-Fudim L, Mostinski Y, Elia J, Cohen S, Steinberg E, et al. Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions. Science Translational Medicine [Internet]. 2023;15(699). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161135909&doi=10.1126%252fscitranslmed.abo0684&partnerID=40&md5=56e4f92d9aafa1f51ed1a85dc641aefb

4.

Stejerean-Todoran I, Gimotty PA, Watters A, Brafford P, Krepler C, Godok T, et al. A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells. Neuro-Oncology [Internet]. 2023;25(4):674–86. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160251494&doi=10.1093%252fneuonc%252fnoac212&partnerID=40&md5=b687fe0d8267eccc5918296bd341d3f6

5.

Babiker H, Borazenci E, Subbiah V, Agarwala S, Algazi A, Schachter J, et al. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clinical Cancer Research [Internet]. 2022;28(23):5079–87. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143180700&doi=10.1158%252f1078-0432.CCR-21-4486&partnerID=40&md5=d8f11a66778f1baaadf2f085bda0e9d2

6.

Molho-Pessach V, Hartshtark S, Merims S, Lotem M, Caplan N, Alfassi H, et al. Giant congenital melanocytic naevus with a novel CUX1–BRAF fusion mutation treated with trametinib. British Journal of Dermatology [Internet]. 2022;187(6):1052–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138146002&doi=10.1111%252fbjd.21851&partnerID=40&md5=586e40edefc25a37c296b5e00a688c49

7.

Shreberk-Hassidim R, Geiger-Maor A, Eisenberg G, Merims S, Hajaj E, Cohen JE, et al. The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma. Immunologic Research [Internet]. 2022;70(6):793–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134701347&doi=10.1007%252fs12026-022-09308-6&partnerID=40&md5=5b4c0ae963dc02a6410e86d7fd71cca2

8.

Sidlik Muskatel R, Pillar N, Godefroy J, Lotem M, Goldstein G. Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy. Frontiers in Pediatrics [Internet]. 2022;10. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85140601317&doi=10.3389%252ffped.2022.940927&partnerID=40&md5=fe1308e996721d782daf12c765b3563c

9.

Shreberk-Hassidim R, Aizenbud L, Lussheimer S, Thomaidou E, Bdolah-Abram T, Merims S, et al. Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma. Dermatologic Therapy [Internet]. 2022;35(10). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135619903&doi=10.1111%252fdth.15747&partnerID=40&md5=8deacd1d5cade4b3f2e679ef595da18f

10.

Zer A, Icht O, Yosef L, Avram D, Jacobi O, Fenig E, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS). Annals of Oncology [Internet]. 2022;33(7):720–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131232289&doi=10.1016%252fj.annonc.2022.03.012&partnerID=40&md5=69ad9d474510dfefda439113f28eaf6a

11.

Labes S, Stupp D, Wagner N, Bloch I, Lotem M, Lahad EL, et al. Machine-learning of complex evolutionary signals improves classification of SNVs. NAR Genomics and Bioinformatics [Internet]. 2022;4(2). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128748938&doi=10.1093%252fnargab%252flqac025&partnerID=40&md5=a91cbe6b3b867a0c3ea20987a0963cd6

12.

Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O, et al. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines [Internet]. 2022;10(4). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128292173&doi=10.3390%252fvaccines10040540&partnerID=40&md5=87602fec69c17d5d6611dba9bb84b18e

13.

Long GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, et al. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. Annals of Oncology [Internet]. 2022;33(2):204–15. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119410881&doi=10.1016%252fj.annonc.2021.10.010&partnerID=40&md5=e79f3be4c7cd87812eb81cc6cc62deae

14.

Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, et al. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer [Internet]. 2021;21(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107257986&doi=10.1186%252fs12885-021-08032-y&partnerID=40&md5=ca34c2d5ca3fc5fd3f78c934e1a3f858

15.

Avner M, Orevi M, Caplan N, Popovtzer A, Lotem M, Cohen JE. COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma. European Journal of Nuclear Medicine and Molecular Imaging [Internet]. 2021;48(8):2659–60. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102313316&doi=10.1007%252fs00259-021-05278-3&partnerID=40&md5=ac3b6dc472107db781762ad0c513fe2a

16.

Hajaj E, Zisman E, Tzaban S, Merims S, Cohen J, Klein S, et al. Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T-cell effector functions. Cancer Immunology Research [Internet]. 2021;9(6):637–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107534659&doi=10.1158%252f2326-6066.CIR-20-0800&partnerID=40&md5=3a989f0b202b7cf6a67a04d260f5f16e

17.

Ghosh S, Nataraj NB, Noronha A, Patkar S, Sekar A, Mukherjee S, et al. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Reports [Internet]. 2021;35(8). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106489367&doi=10.1016%252fj.celrep.2021.109181&partnerID=40&md5=1d4c414f84e8610f3b4ad31b7167d62c

18.

Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology [Internet]. 2021;22(5):655–64. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105831665&doi=10.1016%2fS1470-2045%2821%2900081-4&partnerID=40&md5=b5c13e792ad6da4578ce44e0835fd03e

19.

Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology [Internet]. 2021;22(5):643–54. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105830174&doi=10.1016%2fS1470-2045%2821%2900065-6&partnerID=40&md5=796fb1f9a173280e49d4b6814cbf65de

20.

Maddalena M, Mallel G, Nataraj NB, Shreberk-Shaked M, Hassin O, Mukherjee S, et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2021;118(23). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107765837&doi=10.1073%252fPNAS.2025631118&partnerID=40&md5=95c704fd8434587d343b9e98e94b2405

21.

Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature [Internet]. 2021;592(7852):138–43. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102712469&doi=10.1038%252fs41586-021-03368-8&partnerID=40&md5=0e600c3269384032f0b99f1efc59ebf2

22.

Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, et al. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. Journal of Clinical Investigation [Internet]. 2021;131(20). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118254192&doi=10.1172%252fJCI129466&partnerID=40&md5=5d1f15c9968c4d63e30b6573466ca472

23.

Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, et al. KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer [Internet]. 2020;8(2). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098332760&doi=10.1136%252fjitc-2020-001806&partnerID=40&md5=27732eb7c0cf1881b2bcda871a099989

24.

Kalaora S, Lee JS, Barnea E, Levy R, Greenberg P, Alon M, et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nature Communications [Internet]. 2020;11(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079361151&doi=10.1038%252fs41467-020-14639-9&partnerID=40&md5=0418a7f47e7641c69b773c6e78fb4e85

25.

Kucukkaraduman B, Turk C, Fallacara AL, Isbilen M, Senses KM, Ayyildiz ZO, et al. Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells. ACS Medicinal Chemistry Letters [Internet]. 2020;11(5):928–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080090624&doi=10.1021%252facsmedchemlett.9b00679&partnerID=40&md5=7bba9026c12db074540ae1f6a6d6039f

26.

Hirshoren N, Yoeli R, Cohen JE, Weinberger JM, Kaplan N, Merims S, et al. Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. PLoS ONE [Internet]. 2020;15(4). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083390707&doi=10.1371%252fjournal.pone.0231038&partnerID=40&md5=2e804c2b1e3d4d456aaecaa7c761b0b4

27.

Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, David IB, et al. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. eLife [Internet]. 2020;9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082092774&doi=10.7554%252feLife.52539&partnerID=40&md5=d08eb1b2d358515748b48e3137d46fb2

28.

Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G, et al. Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study. Frontiers in Oncology [Internet]. 2020;10. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080056907&doi=10.3389%252ffonc.2020.00070&partnerID=40&md5=27990c39c92fa0f1cb49c9c94e85841c

29.

Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, et al. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. Journal of Translational Medicine [Internet]. 2019;17(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072979958&doi=10.1186%252fs12967-019-2081-2&partnerID=40&md5=9ef4dcb63db407a2134abd95ad1115ad

30.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncology [Internet]. 2019;20(9):1239–51. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069659047&doi=10.1016%2fS1470-2045%2819%2930388-2&partnerID=40&md5=e59488b0b579cacf7507c65350fbfd09

31.

Pollack RM, Kagan M, Lotem M, Dresner-Pollak R. Baseline TSH level is associated with risk of anti–PD-1–induced thyroid dysfunction. Endocrine Practice [Internet]. 2019;25(8):824–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070471037&doi=10.4158%252fEP-2018-0472&partnerID=40&md5=3513bb7835baf7f207bb106b67dd89b9

32.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine [Internet]. 2019;25(6):941–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066995723&doi=10.1038%252fs41591-019-0448-9&partnerID=40&md5=fc5ee8300ed97f087e6cb42f7cc19bcc

33.

Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, et al. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. Journal of the American Academy of Dermatology [Internet]. 2019;80(6):1780–2. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065640974&doi=10.1016%252fj.jaad.2018.12.020&partnerID=40&md5=8d42d4c790a160de342577a88b35fe24

34.

Weinstein-Marom H, Levin N, Pato A, Shmuel N, Sharabi-Nov A, Peretz T, et al. Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells. Journal of Immunotherapy [Internet]. 2019;42(2):43–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057612820&doi=10.1097%252fCJI.0000000000000252&partnerID=40&md5=6d8575c1fca7b935bed97081979f36de

35.

Levin N, Weinstein-Marom H, Pato A, Itzhaki O, Besser MJ, Eisenberg G, et al. Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40. Journal of Immunology [Internet]. 2018;201(10):2959–68. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056252352&doi=10.4049%252fjimmunol.1701725&partnerID=40&md5=24ed8bc46c345f460da7a8799dc2807c

36.

Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discovery [Internet]. 2018;8(11):1366–75. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055912571&doi=10.1158%252f2159-8290.CD-17-1418&partnerID=40&md5=91663c746b2e4d3945b71c32a1b9649f

37.

Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, et al. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clinical Chemistry and Laboratory Medicine [Internet]. 2018;56(11):1945–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047491798&doi=10.1515%252fcclm-2018-0139&partnerID=40&md5=d881385094b65f076a8e0d1a4f992cbd

38.

Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, et al. Neurologic complications of immune checkpoint inhibitors. Journal of Neuro-Oncology [Internet]. 2018;137(3):601–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041836926&doi=10.1007%252fs11060-018-2752-5&partnerID=40&md5=0325e339c5325dd646fb5960c71a7552

39.

Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, et al. Soluble SLAMF6 receptor induces strong CD8\+ T-cell effector function and improves anti-melanoma activity in vivo. Cancer Immunology Research [Internet]. 2018;6(2):127–38. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041901936&doi=10.1158%252f2326-6066.CIR-17-0383&partnerID=40&md5=79cf70f210b964f8c668b8aa0edad5a4

40.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications [Internet]. 2017;8(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029870193&doi=10.1038%252fs41467-017-00608-2&partnerID=40&md5=8795aa24efa16cd481e201ae6f4950f4

41.

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet [Internet]. 2017;390(10105):1853–62. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027501801&doi=10.1016%2fS0140-6736%2817%2931601-X&partnerID=40&md5=b0ee8a4d148b78ec601258809a99da82

42.

Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, et al. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (United States) [Internet]. 2017;96(20). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020641847&doi=10.1097%252fMD.0000000000006931&partnerID=40&md5=cf2f1deb3e0b8fed91630281bc129466

43.

Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Adoptive cell therapy: Past, present and future. Immunotherapy [Internet]. 2017;9(2):183–96. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011019285&doi=10.2217%252fimt-2016-0112&partnerID=40&md5=1523fd7083449dab720cf306c7670438

44.

Senses KM, Ghasemi M, Akbar MW, Isbilen M, Fallacara AL, Frankenburg S, et al. Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma. MedChemComm [Internet]. 2017;8(1):88–95. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010726065&doi=10.1039%252fc6md00466k&partnerID=40&md5=cc7926902ab5175c0ef85f0b0f5ecc92

45.

Kuint R, Lotem M, Neuman T, Bekker-Milovanov E, Abutbul A, Laxer U, et al. Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report. Respiratory Medicine Case Reports [Internet]. 2017;20:95–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009438154&doi=10.1016%252fj.rmcr.2017.01.003&partnerID=40&md5=c250ad80220a67752bd31f207123b5fa

46.

Levin N, Pato A, Cafri G, Eisenberg G, Peretz T, Margalit A, et al. Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40. Journal of Immunotherapy [Internet]. 2017;40(2):39–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007248150&doi=10.1097%252fCJI.0000000000000150&partnerID=40&md5=ddfcd1e488b4e08f2b2428d646ed7df1

47.

Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical significance of circulating CD33+ CD11bHLA-DR myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clinical Cancer Research [Internet]. 2016;22(23):5661–72. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006282762&doi=10.1158%252f1078-0432.CCR-15-3104&partnerID=40&md5=d348fcfb87ae4742c11191cca7b55384

48.

Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, et al. Immune monitoring of patients treated with a whole-cell melanoma vaccine engineered to express 4-1BBL. Journal of Immunotherapy [Internet]. 2016;39(8):321–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983759364&doi=10.1097%252fCJI.0000000000000138&partnerID=40&md5=93f0686ef1f40e1496b56fe053f719da

49.

Ollech A, Stemmer SM, Merims S, Lotem M, Popovtzer A, Hendler D, et al. Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. International Journal of Dermatology [Internet]. 2016;55(4):473–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960357272&doi=10.1111%252fijd.13153&partnerID=40&md5=656276829c05140c5e6551cb88eab065

50.

Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, et al. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. Journal of Immunology Research [Internet]. 2016;2016. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973131338&doi=10.1155%252f2016%252f8121985&partnerID=40&md5=2c9264f654fc9614b106437795c4c09b

51.

Weinstein-Marom H, Pato A, Levin N, Susid K, Itzhaki O, Besser MJ, et al. Membrane-attached cytokines expressed by mRNA electroporation act as potent T-cell adjuvants. Journal of Immunotherapy [Internet]. 2016;39(2):60–70. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957999011&doi=10.1097%252fCJI.0000000000000109&partnerID=40&md5=953ee7a1605be81fe7e26238e6f362ae

52.

Barak V, Leibovici V, Peretz T, Kalichman I, Lotem M, Merims S. Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. Anticancer research [Internet]. 2015;35(12):6755–60. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973410099&partnerID=40&md5=27fdb24267052896cd937abfa043d064

53.

Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, et al. Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. Clinical and Experimental Immunology [Internet]. 2015;182(2):220–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944168983&doi=10.1111%252fcei.12688&partnerID=40&md5=a1c03302e69cc465d5713a36a8840a17

54.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine [Internet]. 2015;372(26):2521–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929481481&doi=10.1056%252fNEJMoa1503093&partnerID=40&md5=981d13e5a991407ec91c3036a2c2ead2

55.

Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, et al. Human T cell crosstalk is induced by tumor membrane transfer. PLoS ONE [Internet]. 2015;10(2). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923037149&doi=10.1371%252fjournal.pone.0118244&partnerID=40&md5=fb43aecde20a3d0c6db5843ddb9745f6

56.

Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget [Internet]. 2014;5(7):1701–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898942477&doi=10.18632%252foncotarget.1892&partnerID=40&md5=57fc9dbe53b29e422cd307dad7e2fc5c

57.

Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, et al. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. Journal of Immunology [Internet]. 2013;190(11):5856–65. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878044843&doi=10.4049%252fjimmunol.1202879&partnerID=40&md5=de896e392eab267f08d0a6f10c292d4b

58.

Yaacov B, Lazar I, Tayeb S, Frank S, Izhar U, Lotem M, et al. Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. Journal of General Virology [Internet]. 2012;93(8):1664–72. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864045413&doi=10.1099%252fvir.0.043281-0&partnerID=40&md5=f8dd233f40d64b45d9946125a5bd37d1

59.

Lazar I, Perlman R, Lotem M, Peretz T, Ben-Yehuda D, Kadouri L. The clinical effect of the inhibitor of apopotosis protein livin in melanoma. Oncology [Internet]. 2012;82(4):197–204. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858741627&doi=10.1159%252f000334234&partnerID=40&md5=e6f4e2ed6dc54affd8a503d246edbd46

60.

Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, et al. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8 + T cell clones. Journal of Immunology [Internet]. 2012;188(2):632–40. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855986634&doi=10.4049%252fjimmunol.1101429&partnerID=40&md5=d6c00bc49e185db42becf1584ec2b49f

61.

Lotem M, Merims S, Frank S, Ospovat I, Peretz T. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma]. Harefuah [Internet]. 2012;151(10):585–8, 604. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873708258&partnerID=40&md5=c9a9286c9c7e08336a0869119b1d08c3

62.

Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, et al. HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine. Tissue Antigens [Internet]. 2011;78(3):203–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960990261&doi=10.1111%252fj.1399-0039.2011.01709.x&partnerID=40&md5=dc19d598a92517a2793feae03653ce9d

63.

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine [Internet]. 2011;364(26):2517–26. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959772576&doi=10.1056%252fNEJMoa1104621&partnerID=40&md5=c474d3eba7c7129919bf2f56e69b42fa

64.

Eisenberg G, Machlenkin A, Frankenburg S, Mansura A, Pitcovski J, Yefenof E, et al. Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response. Cellular Immunology [Internet]. 2010;266(1):98–103. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77958489663&doi=10.1016%252fj.cellimm.2010.09.003&partnerID=40&md5=9a0df1f703e1c4fe7ebbd7e42c3169b8

65.

Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein livin. Journal of Virology [Internet]. 2010;84(1):639–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-72849135966&doi=10.1128%252fJVI.00401-09&partnerID=40&md5=553be87c46f84ae422406142998a19a5

66.

Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, et al. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunology, Immunotherapy [Internet]. 2010;59(1):103–12. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350121598&doi=10.1007%252fs00262-009-0729-0&partnerID=40&md5=e6a37755e33e5aebe037dba5c9024755

67.

Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, et al. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clinical Cancer Research [Internet]. 2009;15(15):4968–77. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-68049139566&doi=10.1158%252f1078-0432.CCR-08-3320&partnerID=40&md5=fcaa0724f9611fd4cb15eb23d2f7cff5

68.

Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. British Journal of Ophthalmology [Internet]. 2009;93(8):1042–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-68049111254&doi=10.1136%252fbjo.2008.153684&partnerID=40&md5=0013f7593f1c1f9f0cf86708095a3622

69.

Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, et al. Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Familial Cancer [Internet]. 2009;8(1):29–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-59449090970&doi=10.1007%252fs10689-008-9206-8&partnerID=40&md5=6d82e6da2c21e044eedddaffd521aafb

70.

Gross M, Maly B, Maly A, Lotem M, Eliashar R. Metastatic Malignant Melanoma Involving the Parotid Lymph Node Region: A Clinicopathologic Report of 5 Cases. Journal of Oral and Maxillofacial Surgery [Internet]. 2008;66(4):809–13. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-40749083107&doi=10.1016%252fj.joms.2006.10.065&partnerID=40&md5=cc061c4cbadac5837ed5dad2dd0505c1

71.

Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, et al. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Research [Internet]. 2008;68(6):2006–13. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-40949158562&doi=10.1158%252f0008-5472.CAN-07-3119&partnerID=40&md5=3e57a59f0af258794a8adc414fea48ba

72.

Levy A, Pitcovski J, Frankenburg S, Elias O, Altuvia Y, Margalit H, et al. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response. Cellular Immunology [Internet]. 2007;250(1–2):24–30. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-40949101281&doi=10.1016%252fj.cellimm.2008.01.001&partnerID=40&md5=c79427304b87a53908df648ca7855df1

73.

Molho-Pessach V, Lotem M. Ultraviolet radiation and cutaneous carcinogenesis. Current Problems in Dermatology [Internet]. 2007;35:14–27. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547541145&doi=10.1159%252f0000106407&partnerID=40&md5=6b7d7394c0a6cf3cff6b8d0dc3676aee

74.

Molho-Pessach V, Lotem M. Viral carcinogenesis in skin cancer. Current Problems in Dermatology [Internet]. 2007;35:39–51. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547510475&doi=10.1159%252f0000106409&partnerID=40&md5=f496480de1246bbb6b8b7b75fb792702

75.

Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4+ T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Research [Internet]. 2007;67(9):4499–506. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34249323028&doi=10.1158%252f0008-5472.CAN-06-3770&partnerID=40&md5=c6707427f42ababf9048d912efc8b4e8

76.

Salah Z, Maoz M, Pokroy E, Lotem M, Bar-Shavit R, Uziely B. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Molecular Cancer Research [Internet]. 2007;5(3):229–40. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34147206365&doi=10.1158%252f1541-7786.MCR-06-0261&partnerID=40&md5=ad93d055084aa98dc0c8e1af9f1fced6

77.

Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. Journal of Immunotherapy [Internet]. 2006;29(6):616–27. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750571162&doi=10.1097%252f01.cji.0000211312.36363.56&partnerID=40&md5=2e7ce110c02ca55e7f03f281dfc80c3a

78.

Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients. Annals of Oncology [Internet]. 2006;17(4):578–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645288846&doi=10.1093%252fannonc%252fmdl009&partnerID=40&md5=2696a83319cce91a9774e2b3c515d811

79.

Enk CD, Lotem M, Gimon Z, Hochberg M. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Research [Internet]. 2004;14(5):361–5. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-7244248962&doi=10.1097%252f00008390-200410000-00005&partnerID=40&md5=88e970a343622371488c28b2b11490b4

80.

Frankenburg S, Elias O, Gelbart Y, Drize O, Lotem M, Ingber A, et al. Recombinant hydrophilic human gp100: Uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients. Immunology Letters [Internet]. 2004;94(3):253–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-3242714046&doi=10.1016%252fj.imlet.2004.05.014&partnerID=40&md5=55ce3b8283080d94f8636c6d23c76e21

81.

Hodak E, Gottlieb AB, Segal T, Maron L, Lotem M, Feinmesser M, et al. An open trial of climatotherapy at the dead sea for patch-stage mycosis fungoides. Journal of the American Academy of Dermatology [Internet]. 2004;51(1):33–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-3042781169&doi=10.1016%252fj.jaad.2003.11.052&partnerID=40&md5=1e0cc5d29ee00f5bed53712fd872e5ba

82.

Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. British Journal of Cancer [Internet]. 2004;90(4):773–80. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-1642403868&doi=10.1038%252fsj.bjc.6601563&partnerID=40&md5=b4f4daa70fcc158e6654289c1d84b87a

83.

Lieberman S, Goldin E, Lotem M, Bloom AI. Irrigation of the bile ducts with chilled saline during percutaneous radiofrequency ablation of a hepatic ocular melanoma metastasis. American Journal of Roentgenology [Internet]. 2004;183(3):596–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-4344648650&doi=10.2214%252fajr.183.3.1830596&partnerID=40&md5=eb06ad974c2d4fa5227048d522c619f3

84.

Gelbart Y, Frankenburg S, Pinchasov Y, Krispel S, Eliahu D, Drize O, et al. Production and purification of melanoma gp100 antigen and polyclonal antibodies. Protein Expression and Purification [Internet]. 2004;34(2):183–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-12144286025&doi=10.1016%252fj.pep.2003.12.006&partnerID=40&md5=bd1b703b35b831ee3da877d972388a86

85.

Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al. Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Research [Internet]. 2003;63(19):6340–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141954004&partnerID=40&md5=a243622c9140e06e94bb95f826e3bc87

86.

Lotem M, Yehuda-Gafni O, Butnaryu E, Drize O, Peretz T, Abeliovich D. Cytogenetic analysis of melanoma cell lines: Subclone selection in long-term melanoma cell cultures. Cancer Genetics and Cytogenetics [Internet]. 2003;142(2):87–91. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0344406213&doi=10.1016%2fS0165-4608%2802%2900798-7&partnerID=40&md5=a3be9ea524899273c846dd358f70a93c

87.

Lotem M, Anteby S, Peretz T, Ingber A, Avinoach I, Prus D. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecologic Oncology [Internet]. 2003;88(1):45–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037225395&doi=10.1006%252fgyno.2002.6848&partnerID=40&md5=c3101658daf2ad6bc69368a869a209ff

88.

Lotem M, Peretz T, Drize O, David IB, Hamburger T, Gimmon Z. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). British Journal of Cancer [Internet]. 2002;86(10):1534–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-18444397729&doi=10.1038%252fsj.bjc.6600251&partnerID=40&md5=b79fea9402908aaaaf29e6c8e46df014

89.

Hochberg M, Lotem M, Gimon Z, Shiloni E, Enk CD. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. British Journal of Dermatology [Internet]. 2002;146(2):244–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036211285&doi=10.1046%252fj.1365-2133.2002.04579.x&partnerID=40&md5=07929f5f567e292542889c68b90e1dc5

90.

Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, et al. CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. Journal of Immunology [Internet]. 2002;168(6):2803–10. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037087297&doi=10.4049%252fjimmunol.168.6.2803&partnerID=40&md5=a503915b4438ce3341bfeaa8253106fe

91.

Lotem M, Peretz T, Drize O, David IB, Hamburger T, Gimmon Z. Special section on nonparametric approach to time series analysis. Annals of the Institute of Statistical Mathematics [Internet]. 2002;54(1):169. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016852019&doi=10.1023%252fA%253a1016178024370&partnerID=40&md5=6ab71e3847a174e012b94e347226dc40

92.

Lotem M, Raben M, Zeltser R, Landau M, Sela M, Wygoda M, et al. Kindler syndrome complicated by squamous cell carcinoma of the hard palate: Successful treatment with high-dose radiation therapy and granulocyte-macrophage colony-stimulating factor [18]. British Journal of Dermatology [Internet]. 2001;144(6):1284–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035724198&doi=10.1046%252fj.1365-2133.2001.04262.x&partnerID=40&md5=4253ae50f90080f4c7313709dc5c60c2

93.

Pappo I, Lotem M, Klein M, Orda R. Bolus high dose interleukin-2 for the treatment of malignant melanoma. Israel Medical Association Journal [Internet]. 2001;3(3):169–73. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035030144&partnerID=40&md5=992371ce638726cc9bd57bfa163fd8f1

94.

Hazzan D, Reissmann P, Halak M, Resnick MB, Lotem M, Shiloni E. Primary rectal malignant melanoma: Report of two cases. Techniques in Coloproctology [Internet]. 2001;5(1):51–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034974848&doi=10.1007%252fPL00012125&partnerID=40&md5=68cfc979038a3b5e825a5d099abff080

95.

Yakobson E, Shemesh P, Azizi E, Winkler E, Lassam N, Hogg D, et al. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. European Journal of Human Genetics [Internet]. 2000;8(8):590–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033884769&doi=10.1038%252fsj.ejhg.5200505&partnerID=40&md5=0cf6da76ad31d8c7338b88d101aeca68

96.

Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer [Internet]. 2000;89(5):1037–47. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034284335&doi=10.1002%2f1097-0142%2820000901%2989%3a5%3c1037%3a%3aAID-CNCR13%3e3.0.CO%3b2-Z&partnerID=40&md5=861683b7d58fc9d6ee6de2e74260692b

97.

Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Archives of Dermatology [Internet]. 2000;136(12):1475–80. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034529887&doi=10.1001%252farchderm.136.12.1475&partnerID=40&md5=6bf7977660b60954a01747c8af55baae

98.

Klein M, Freedman N, Lotem M, Marciano R, Moshe S, Gimon Z, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: A pilot study. NuklearMedizin [Internet]. 2000;39(3):56–61. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034111940&doi=10.1055%252fs-0038-1632245&partnerID=40&md5=ccd32f048a9b1ff06e8fb3ffe80a59e4

99.

Hirshberg B, Kramer MR, Lotem M, Barak V, Shustin L, Amir G, et al. Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma. American Journal of Hematology [Internet]. 1999;60(2):143–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032930652&doi=10.1002%2f%28SICI%291096-8652%28199902%2960%3a2%3c143%3a%3aAID-AJH11%3e3.0.CO%3b2-Q&partnerID=40&md5=d895a98e6106b3d44ee2c6a3341c4dca

100.

Lotem M, Shiloni E, Ingber A, Peretz T. Active specific immunotherapy of malignant melanoma. Harefuah [Internet]. 1997;133(3–4):122–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031205464&partnerID=40&md5=6b90b097cd0e119d1de7f337df2725b4

101.

Tsur A, Sazbon L, Lotem M. Relationship between muscular tone, movement and periarticular new bone formation in postcoma-unaware (PC-U) patients. Brain Injury [Internet]. 1996;10(4):259–62. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029991426&doi=10.1080%252f026990596124430&partnerID=40&md5=5f53bd77e52ff114d78d6ba1fb6b8016

102.

Lotem M, Tamir G, Loven D, David M, Hauben D. Multiple basal cell carcinomas of the leg after recurrent erysipelas and chronic lymphedema. Journal of the American Academy of Dermatology [Internet]. 1994;31(5):812–3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028117060&doi=10.1016%2fS0190-9622%2809%2980052-2&partnerID=40&md5=7840be0ce8b4d25175ebda3c7d648bf0

103.

Lotem M, Trattner A, Ingber A. Paraneoplastic Pemphigus: Reevaluation of a Case From the Past. Archives of Dermatology [Internet]. 1994;130(11):1454. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028006670&doi=10.1001%252farchderm.1994.01690110124030&partnerID=40&md5=eaa279730060263fa81933a446719814

104.

Tsur A, Sazbon L, Lotem M. Influence of muscle tone and force on ossification in postcomatose patients. Harefuah [Internet]. 1992;123(3–4):86–9, 156–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026904646&partnerID=40&md5=fd04b31dba13a2e2da8af33f38ee1106

105.

LOTEM M, TRATTNER A, KAHANOVICH S, ROTEM A, SANDBANK M. MULTIPLE DERMAL CYLINDROMA UNDERGOING A MALIGNANT TRANSFORMATION. International Journal of Dermatology [Internet]. 1992;31(9):642–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026787462&doi=10.1111%252fj.1365-4362.1992.tb03985.x&partnerID=40&md5=a3987c02251458dbb458ba749545425f

106.

Lotem M, Birch JG, Herring JA, Roach JW, Johnston II CE, Viere RG. Letter to the editor [3]. Journal of Bone and Joint Surgery - Series A [Internet]. 1991;73(3):472. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026351811&partnerID=40&md5=d2f4ad9eb0d67b2381512bfe688e22bf

107.

Lotem M, Ingber A, Segal R, Sandbank M. Generalized pustular drug rash induced by hydroxychloroquine. Acta Dermato-Venereologica [Internet]. 1990;70(3):250–1. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025300031&partnerID=40&md5=f0e2ffa375542765c19761f9186a42bb

108.

Katzenelson V, Lotem M, Sandbank M. Familial lichen planus. Dermatologica [Internet]. 1990;180(3):166–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025219937&partnerID=40&md5=d20f68ea43ba5fefdba415e24a6dede5

109.

Halevy S, Arie R, Ingber A, Lotem M, Sandbank M. Analysis of lithogenous factors in lichen planus. Acta Dermato-Venereologica [Internet]. 1990;70(5):441–2. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025075125&partnerID=40&md5=52babf87a5dc528bde6946b5735ffba9

110.

Lotem M, Ingber A, Sandbank M, Hazaz B. Lichen Planus Pemphigoides With Features of Lichen Planus and Pemphigus Vulgaris. Archives of Dermatology [Internet]. 1989;125(5):707–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024672818&doi=10.1001%252farchderm.1989.01670170123025&partnerID=40&md5=d73126d40c8277d966ff2021acb61142

111.

Lotem M, Katzenelson V, Sandbank M, Hod M, Sandbank M. Impetigo herpetiformis: A variant of pustular psoriasis or a separate entity? Journal of the American Academy of Dermatology [Internet]. 1989;20(2):338–41. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024568754&doi=10.1016%2fS0190-9622%2889%2970042-6&partnerID=40&md5=8cf2f69ddf19b2eac26135d99ad59a9b

112.

Lotem M, Ingber A, Filhaber A, Sandbank M. Skin infection provoked by coagulase-negative Staphylococcus resembling gram-negative folliculitis. Cutis [Internet]. 1988;42(5):443–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024237347&partnerID=40&md5=b901af4eb6e01cf21d60f8c4066ecdbd

113.

Davidovitch E, Lotem M, Hallel T. Malignant fibrous histiocytoma. Harefuah [Internet]. 1988;115(1–2):13–5. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024039942&partnerID=40&md5=b040a1e1868d1edc1825d819beb9b489

114.

Sagiv P, Lotem M, Solan H, Hallel T. Metatarsus adductus–incidence and treatment. Harefuah [Internet]. 1986;110(8):394–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023049372&partnerID=40&md5=ba3ab3f85dcee29acdf960b4a10113d8

115.

Houpt JB, Alpert B, Lotem M, Greyson ND, Pritzker KP, Langer F, et al. Spontaneous osteonecrosis of the medial tibial plateau. Journal of Rheumatology [Internet]. 1982;9(1):81–90. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020317601&partnerID=40&md5=2ed9036d9a105ca3c4bb9f2ae22fa69f

116.

Groswasser Z, Lotem M, Mendelson L. Treatment of femoral fractures in patients with craniocerebral injury. International Surgery [Internet]. 1982;67(4 Suppl.):556–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020309061&partnerID=40&md5=4ec02fb436c0e469f7ddd0f9b87acdc8

117.

Greyson ND, Lotem MM, Gross AE, Houpt JB. Radionuclide evaluation of spontaneous femoral osteonecrosis. Radiology [Internet]. 1982;142(3):729–35. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020041514&doi=10.1148%252fradiology.142.3.7063692&partnerID=40&md5=b244c7ae8c1b6dfe4137d909cda75615

118.

Lotem M, Davidovitz E. Malignant fibrous histiocytoma. Harefuah [Internet]. 1980;98(5):216-218+239. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018927491&partnerID=40&md5=9f1a303be9648fb57bb87ac5771ea43e

119.

Conforty B, Lotem M. Ossicles in human menisci: report of two cases. Clinical Orthopaedics and Related Research [Internet]. 1979;(144):272–5. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018525982&partnerID=40&md5=4673d4c13c6a066a8ced4f26668369a9

120.

Lotem M, Bernheim J, Conforty B. Spontaneous rupture of tendons. A complication of hemodialyzed patients treated for renal failure. Nephron [Internet]. 1978;21(4):201–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018100544&partnerID=40&md5=19965e4d07b9e90f17aa77936be891de

121.

Lotem M. Medical aspects and prevention of road accidents and the treatment of the injured. Family Physician [Internet]. 1976;5(3):36. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0017077079&partnerID=40&md5=01b49e097b06200306a98fe6dd522ccc

122.

Lotem M, Conforty B. High pressure injection injuries of the hand (Hebrew). Harefuah [Internet]. 1975;89(5):213-215+239. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0016774871&partnerID=40&md5=fb537979f07762d8a5b2c0dd0eee6d97

123.

Lotem M, Wolloch J. Postoperative peripheral nerve injury. Harefuah [Internet]. 1975;88(8):379–80. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0016852597&partnerID=40&md5=c0e9d8c066fcf57d2bfd0fc2c15805ed

124.

Lotem M, Solzi P. The carpal tunnel syndrome (Hebrew). Family Physician [Internet]. 1975;5(1):61-63+12. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0016775587&partnerID=40&md5=be6751c614aa5abaac78bc54ec9248ca

125.

Lotem M, Robson MD, Rosenfeld JB. Spontaneous rupture of the quadriceps tendon in patients on chronic haemodialysis. Annals of the Rheumatic Diseases [Internet]. 1974;33(5):428–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0016271292&doi=10.1136%252fard.33.5.428&partnerID=40&md5=49b6e3545d1a47315fc10a96099cb380

126.

Lotem M, Maor P, Levi M. Rupture of the extensor tendons of the hand in lupus erythematosus disseminatus. Annals of the Rheumatic Diseases [Internet]. 1973;32(5):457–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015896634&doi=10.1136%252fard.32.5.457&partnerID=40&md5=a2f004f520d6f45ffcfdc270060dd8b7

127.

Levy M, Pauker M, Lotem M, Seelenfreund M, Fried A. High tibial osteotomy: a follow up study and description of a modified technic. CLINORTHOP [Internet]. 1973;93:274–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015894957&doi=10.1097%252f00003086-197306000-00031&partnerID=40&md5=a80967042749b870a75b994a157853b8

128.

Pauker M, Lotem M, Levy M, Luria M. BCG arthritis and osteomyelitis. Harefuah [Internet]. 1972;83(10):429–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015511467&partnerID=40&md5=c2fbc3f8d55a25c027e7eb22227c84e0

129.

Lotem M, Fried A, Solzi P, Natanson T. Saturday night palsy. Harefuah [Internet]. 1972;83(8):328. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015511077&partnerID=40&md5=433f400499d84c8b832491f48b9184f2

130.

Maor P, Levy M, Lotem M, Fried A. Iatrogenic Volkmann’s ischemia–a result of pressure-transfusion. International Surgery [Internet]. 1972;57(5):415–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015335858&partnerID=40&md5=f5679a6a8f5cbcd4ca7cd0bc32f650b9

131.

Fried A, Lotem M. Local infiltration anesthesia for meniscectomy. Clinical orthopaedics and related research [Internet]. 1972;87:204–5. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015398757&doi=10.1097%252f00003086-197209000-00024&partnerID=40&md5=a09ee2d0789daef970a9974a5d265f65

132.

Lotem M, Maor P, Fried A. Posterior interosseous nerve palsy. Harefuah [Internet]. 1971;81(8):377–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015227495&partnerID=40&md5=b89da062b2b908e3b53d0e184f6b4046

133.

Lotem M, Fried A. Operative treatment of degenerative tears of the semilunar cartilage. A follow-up study. Israel Journal of Medical Sciences [Internet]. 1971;7(6):733–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015073613&partnerID=40&md5=2ca7ce17139edaa2f5df9c88d88b8e51

134.

Lotem M, Maor P, Haimoff H, Woloch Y. Lumbar hernia at an iliac bone graft donor site. A case report. Clinical orthopaedics and related research [Internet]. 1971;80:130–2. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015138878&doi=10.1097%252f00003086-197110000-00018&partnerID=40&md5=01fa37c5f31b8b820829cdad66b26eae

135.

Lotem M, Fried A, Levy M, Solzi P, Najenson T, Nathan H. Radial palsy following muscular effort. A nerve compression syndrome possibly related to a fibrous arch of the lateral head of the triceps. The Journal of bone and joint surgery British volume [Internet]. 1971;53(3):500–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015108106&doi=10.1302%252f0301-620x.53b3.500&partnerID=40&md5=17dfe664acc4cef25e6a8751c7d173e9

136.

Lotem M, Solsi P. Transient radial palsy following muscular effort. Harefuah [Internet]. 1970;78(10):490–1. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0014947489&partnerID=40&md5=ef81d40757f73128d762f6d57d5fd5ab

137.

Levy M, Lotem M, Fried A. The Laurence-Moon-Biedl-Bardet syndrome. Report of three cases in a Jewish Yemenite family. The Journal of bone and joint surgery British volume [Internet]. 1970;52(2):318–24. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0014784055&doi=10.1302%252f0301-620x.52b2.318&partnerID=40&md5=bdb5610bc0656ce7ce39294fb2f7c6a2